Diabetes, Healthy
Conditions
Brief summary
This trial was conducted in Asia. The aim of this trial was to investigate the pharmacokinetic properties (the effect of the investigated drug on the body) of NN1250 (insulin degludec) in healthy Chinese subjects.
Interventions
DRUGinsulin degludec
For each subject, a single dose of NN1250 will be administered subcutaneously (under the skin)
Sponsors
Novo Nordisk A/S
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
No
Inclusion criteria
* Male or female Chinese subject aged 18-45 years (both inclusive) * Considered generally healthy upon completion of medical history, physical examination, vital signs and electrocardiogram (ECG), as judged by the Investigator * Body mass index 19.0-24.0 kg/m\^2 (both inclusive)
Exclusion criteria
* A history of any illness that, in the opinion of the Investigator, might confound the results of the trial or pose risk in administering the trial product to the subject * Subject who has donated any blood or plasma in the past month or more than 400 mL within 3 months prior to screening * Not able or willing to refrain from smoking during the inpatient period
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area under the serum insulin degludec concentration-time curve | From 0 to 120 hours after single dose |
Secondary
| Measure | Time frame |
|---|---|
| Maximum observed serum insulin degludec concentration | 0-24 hours (derived on treatment day 1). |
| Time to maximum observed serum insulin degludec concentration | 0-24 hours (derived on treatment day 1). |
Countries
China
Outcome results
None listed